Topics

Companies Related to "potential approach type diabetes treatment" [Most Relevant Company Matches] RSS

17:28 EST 11th December 2019 | BioPortfolio

Here are the most relevant search results for "potential approach type diabetes treatment" found in our extensive corporate database of over 50,000 company records.

Showing "potential approach type diabetes treatment" Companies 1–25 of 6,200+

Extremely Relevant

Exsulin Corporation

Based in Minneapolis, Exsulin Corporation has global rights to and pioneered the development of an experimental approach for the treatment of Type 1 and Type 2 diabetes with the goal of affecting the future of diabetes care and providing significant cost savings within the healthcare system. Exsulin has worked with leading research labs in multiple countries to develop the technology that has led ...


MannKind

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, Technosphere® Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. This therapy consists of a propri...

Relevant

T1D Exchange

T1D Exchange was founded on the belief that people affected by type 1 diabetes need better solutions faster – better treatments and better care. Our nonprofit organization takes an innovative approach that puts the community of people touched by type 1 diabetes at the center of research that will meaningfully impact their lives. Our integrated model ...


Omni Bio Pharmaceutical, Inc.

Omni Bio Pharmaceutical, Inc. (www.omnibiopharma.com) is an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential. Omni Bio's core technology and pipeline are based on issued and pending patents licensed from the University of Colorado Denver ("UCD") and a privately held corporation surrounding the...

Virta Health

Virta is online specialty medical clinic that reverses type 2 diabetes safely and sustainably, without the risks, costs, or side effects of medications or surgery. Drawing on decades of research, including that of our founders and advisors, Virta is driving two major innovations. First, we take a highly individualized approach to metabolic health, focused ...

GI Dynamics, Inc.

GI Dynamics is focused on the development and commercialization of effective, non-surgical treatments for type 2 diabetes and obesity. The company’s patented EndoBarrier® technology has the potential to deliver effective treatments for people combating weight problems and diabetes or diabetes risk factors.

AutoImmune Incorporated

AutoImmune Inc. is a biopharmaceutical company developing a new class of orally administered pharmaceutical productsfor the treatment of autoimmune and other cell-mediated inflammatory diseases and conditions. At the start of 1999 the Company was conducting clinical trials for the following products: Colloral(R), for the treatment of rheumatoid arthritis, and AI 502, for the treatment of chronic t...

DreaMed Diabetes

DreaMed Diabetes was established in 2014 to develop and commercialize diabetes treatment and management solutions. Its flagship product, GlucoSitter™, is a closed-loop insulin delivery system for patients with type 1 and type 2 diabetes. Additional development programs include insulin-treatment-profiling systems for diabetic clinics, patient decision-...

Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Betagenon AB

Betagenon has secured a strong, proprietary technology platform based upon the extensive research expertise on type 2 diabetes disease mechanisms established by the Founders, leading experts in the field. Betagenon's vision is to become a frontier company that delivers new smart drug platform solutions to the pharmaceutical industry for treatment of the metabolic syndrome and diabetes type 2. Afte...

Bristol-Myers Squibb Company & AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Bristol-Myers Squibb Company and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Bristol-Myers Squibb and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Diabetes Hands Foundation

TuDiabetes.org was co-founded in 2007 by Manny Hernandez, a diabetes advocate and social media expert diagnosed with type 1 diabetes in 2002. The community is run by the Diabetes Hands Foundation, a 501c3 nonprofit that connects people touched by diabetes and raises diabetes awareness.

Team Type 1 Foundation

Established in 2013, the Team Type 1 Foundation is a nonprofit organization pursuing a mission of education, empowerment and equal access to medicine for everyone affected by diabetes. Collaborating with governments, healthcare professionals, diabetes experts and individuals living with diabetes around the world, the Team Type 1 Foundation is bridging the ...

DiObex

DiObex, Inc., a clinical-stage company based in San Francisco, is developing unique, first-in-class therapies for the critically under-served metabolic disease market. Our pipeline products address the markets for the treatment of type 1 diabetes, type 2 diabetes and its co-morbidities such as hypertension, dyslipidemia and visceral adiposity (often referred to collectively as “metabolic syndrom...

Glucox Biotech AB

The primary goal of Glucox Biotech is to develop a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance. The highly favorable benefits of Glucox Biotech therapy is to decrease the critical risks and delay progression of the complications in Type 2 Diabetes patients by improving glycemic blood control. Based on its scientific excellence and with a strong mi...

Creative Peptides develops pharmaceutical products

Creative Peptides develops pharmaceutical products based on C-peptide Our research will significantly improve on the treatment of long-term complications of type 1 diabetes. Complications of type 1 diabetes are currently not effectively and safely treatable and cause great suffering in afflicted patients as well as vast costs to society

Thetis Pharmaceuticals, LLC

Thetis Pharmaceuticals is a privately held biopharmaceutical company applying its expertise in amino-lipid chemistry to discover and develop innovative drugs for the treatment of cardio-metabolic diseases. Thetis uses its proprietary HEALER platform to transform approved drugs or previously studied biologically active agents into new chemical entities with...

The T1D Exchange

The T1D Exchange is a unique platform for collaborative data collection and sharing that consists of three overlapping components: a clinic-based registry with clinical, biological and other real-life information from individuals with type 1 diabetes, a registry that is coordinated through a network of clinical centers and an interactive online community f...

Tolerx, Inc.

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKli...

Diabetes & Glandular Disease Clinic of San Antonio

The Diabetes & Glandular Disease Clinic, P.A. (DGD) offers the best in treatment for hormonal and metabolic disorders such as type 1 and 2 diabetes, gestational diabetes, thyroid disease, osteoporosis, lipid disorders (high cholesterol), pituitary/adrenal gland problems, menstrual disorders and hirsutism (excessive facial hair on women). All our doctors are board-certified in Endocrinology & Metab...

Takeda San Diego

Takeda San Diego (TSD) is Takeda's global center for excellence in structure-based drug discovery. TSD integrates cutting-edge protein crystallography and drug discovery technologies to efficiently generate Investigational New Drug (IND) candidates for the treatment of metabolic diseases and cancer. Multiple drug candidates discovered at TSD are currently in clinical trials including SYR322, a pot...

Waratah Pharmaceuticals

Waratah is a dynamic young biopharmaceutical company founded in April 2000 as a spin-off of RTP Pharma Inc. to develop and commercialize products for its novel, patented therapy – Islet Neogenesis Therapy (I.N.T.™) for the treatment of insulin-dependent diabetes. Diabetes is a disease in which the body does not produce or properly use insulin because of damaged or destroyed insulin producing i...

GI Dynamics

GI Dynamics is focused on developing effective, non-surgical approaches for treating type 2 diabetes and obesity. The company’s patented EndoBarrier™ Technology has the potential to deliver medical interventions for patients combating weight problems and diabetes or diabetes risk factors. Data from clinical trials demonstrate that the EndoBarr...


More From BioPortfolio on "potential approach type diabetes treatment"

Quick Search

Corporate Database Quicklinks